Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
151.40
+0.28 (0.19%)
At close: Feb 20, 2026, 4:00 PM EST
152.30
+0.90 (0.59%)
After-hours: Feb 20, 2026, 7:57 PM EST
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,672,898
Profits / Employee
$483,523
Market Cap
187.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 92,900 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
GILD News
- 16 hours ago - Time To Take Profits On Gilead Sciences (Rating Downgrade) - Seeking Alpha
- 3 days ago - Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options - Business Wire
- 9 days ago - Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
- 10 days ago - Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance - Benzinga
- 10 days ago - Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ
- 10 days ago - Gilead quarterly results beat Wall Street estimates - Reuters
- 10 days ago - Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend - Business Wire